Compare Neurocrine Biosciences Inc (NBIX) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Newmont Corporation — how do they compare? Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B), while Newmont Corporation trades at $120.23 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 7.5× Neurocrine Biosciences Inc's market cap, and Newmont Corporation pays a 0.89% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NEM | |
|---|---|---|
Market Cap | $16.46B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $131.95 |
52-Week Low | $123.10 | $67.38 |
Enterprise Value | $16.48B | $120.09B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Newmont Corporation (NEM) trades at $117.26, up 3.79% over 24 hours, near its 52-week high. The stock exhibits strong bullish technical signals and robust fundamentals, with revenue growing to $22.67 billion in 2025 and net income reaching $7.09 billion. Recent news highlights the resolution of a Nevada joint venture dispute with Barrick Mining, providing operational clarity.
The outlook for NEM remains positive, supported by strong earnings beats, a favorable analyst consensus, and rising gold prices. Key risks include gold price volatility and execution of production targets. The consensus price target of $133.00 suggests upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
